Targeting stearoyl-CoA desaturase 1 to repress endometrial cancer progression
Weihua Li1,2, Huimin Bai2, Shiping Liu3
1Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Wangfujing, Beijing 100730, China.
Abstract:
Stearoyl-CoA desaturase 1 (SCD1) is an established molecular target in many primary tumors including breast, lung, pancreatic, colon and hepatocellular carcinomas. However, its potential role in supporting endometrial cancer growth and progression has not yet been determined. In this study, we evaluated the value of SCD1 as a candidate therapeutic target in human endometrial cancer. Compared with secretory and post-menopausal endometrium, SCD1 was highly expressed in normal endometrium of proliferative phase, endometrial hyperplasia and endometrial carcinoma, while was absent or low expression in non-malignant control stromal cells and adjacent normal endometrium. Knockdown of SCD1 significantly repressed endometrial cancer cell growth and induced cell apoptosis. Both short hairpin RNA targeted knockdown and chemical inhibitor of SCD1 suppressed the foci formation of AN3CA, a metastatic endometrial cell line. Xenograft model further demonstrated that reduced SCD1 expression impaired endometrial cancer growth in vivo. Taken together, these findings indicate that SCD1 is a potentially therapeutic target in human endometrial cancer. Inhibiting lipid metabolism in cancer cells would be a promising strategy for anti-cancer therapy.
Insights
Stearoyl-CoA desaturase 1 (SCD1) is highly expressed in endometrial cancer. Inhibiting SCD1 repressed cancer cell growth and impaired tumor progression, indicating its potential as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Stearoyl-CoA desaturase 1 (SCD1) is a key enzyme in lipid metabolism and a known target in various cancers.
- The role of SCD1 in endometrial cancer progression remains largely unexplored.
Purpose of the Study:
- To investigate the expression and functional significance of SCD1 in human endometrial cancer.
- To evaluate SCD1 as a potential therapeutic target for endometrial cancer treatment.
Main Methods:
- SCD1 expression analysis in normal endometrium, hyperplasia, and endometrial carcinoma tissues.
- In vitro studies using short hairpin RNA (shRNA) and chemical inhibitors to knockdown SCD1 in endometrial cancer cell lines.
- In vivo xenograft models to assess the effect of SCD1 inhibition on tumor growth.
Main Results:
- SCD1 was highly expressed in endometrial hyperplasia and carcinoma compared to normal endometrium.
- SCD1 knockdown significantly inhibited endometrial cancer cell proliferation and induced apoptosis.
- Inhibition of SCD1 suppressed foci formation in a metastatic endometrial cell line and impaired tumor growth in vivo.
Conclusions:
- SCD1 is upregulated in endometrial cancer and plays a crucial role in cancer cell growth and progression.
- Targeting SCD1 represents a promising therapeutic strategy for endometrial cancer by disrupting lipid metabolism.
More Related Videos
05:52Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Repressed Memory
Repressible Operon: trp Operon
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
SN1 Reaction: Stereochemistry
In the first step of an SN1 reaction, the bond between the electrophilic carbon and the leaving group ionizes to generate the carbocation intermediate. The second step of the mechanism is the nucleophilic attack.
In the formed carbocation, the positively charged carbon is sp2 hybridized with a trigonal planar geometry. As all the three substituents lie on the same plane, a plane of symmetry for the...
